Rigel Pharmaceuticals Ownership | Who Owns Rigel Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Rigel Pharmaceuticals Ownership Summary


Rigel Pharmaceuticals is owned by 13.28% institutional investors, 2.43% insiders, and 84.29% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 9.23% of RIGL shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 4.07% of its assets in Rigel Pharmaceuticals shares.

RIGL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockRigel Pharmaceuticals13.28%2.43%84.29%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de1.66M9.23%$71.28M
Vanguard group1.04M5.76%$44.48M
Armistice capital724.00K4.05%$20.51M
Goldman sachs group671.88K3.72%$28.78M
Marshall wace, llp601.33K3.36%$17.04M
Capitolis liquid global markets591.55K3.31%$16.76M
State street554.32K3.10%$15.70M
Lsv asset management544.28K3.02%$23.31M
Renaissance539.01K2.99%$23.09M
Acadian asset management493.60K2.74%$21.13M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Cm management225.00K8.12%$9.64M
Globeflex capital l p217.84K1.43%$9.33M
Empire financial management company76.44K0.71%$3.27M
Range financial group45.94K0.68%$1.97M
Hussman strategic advisors52.50K0.54%$2.25M
Soleus capital management300.03K0.47%$12.85M
Hillsdale investment management282.58K0.33%$12.10M
Pharvision advisers20.52K0.33%$581.39K
Armistice capital724.00K0.30%$20.51M
Wakefield asset management lllp25.65K0.30%$1.10M

Top Buyers

HolderShares% AssetsChange
Lsv asset management544.28K0.05%433.38K
Marshall wace, llp601.33K0.02%232.38K
Arrowstreet capital, limited partnership413.66K0.01%227.33K
Qube research360.97K0.01%189.54K
Two sigma investments, lp220.30K0.01%181.96K

Top Sellers

HolderShares% AssetsChange
Blackrock---14.80M
Nuveen asset management---3.22M
Jacobs levy equity management---2.29M
Healthcare of ontario pension plan trust fund---1.36M
Stonepine capital management---1.04M

New Positions

HolderShares% AssetsChangeValue
Schroder investment management group71.82K0.00%71.82K$2.06B
First trust advisors lp57.62K0.00%57.62K$1.63M
Universal- beteiligungs- und servicegesellschaft mbh55.20K0.00%55.20K$2.36M
Hussman strategic advisors52.50K0.54%52.50K$2.25M
Hennion & walsh asset management52.19K0.08%52.19K$2.24M

Sold Out

HolderChange
Financial consulate-10.00
Synergy asset management-15.00
Strategic investment solutions, inc. /il-25.00
Harbour investments-40.00
Gps wealth strategies group-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202545-73.53%2,395,282-84.02%130.19%33-68.27%9-80.43%
Sep 30, 202548-61.29%2,467,259-82.23%130.23%24-61.90%14-61.11%
Jun 30, 20251230.82%13,882,606-0.14%771.27%62-3.13%36-5.26%
Mar 31, 20253-97.60%1,156,951-90.41%60.14%1-98.78%1-95.24%
Dec 31, 2024650.00%1,21265.35%-39369.05%2100.00%--

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF738.73K4.07%-3.98K
Vanguard US Total Market Shares ETF548.78K3.07%-
Vanguard Total Stock Mkt Idx Inv542.05K2.99%6.80K
iShares Russell 2000 ETF428.34K2.36%59.60K
Avantis US Small Cap Value ETF417.88K2.30%1.17K
GS Glb Sm Cp CORE Eq Base Inc USD Close290.18K1.60%-
SPDR® S&P Biotech ETF223.01K1.24%500.00
Vanguard Institutional Extnd Mkt Idx Tr195.09K1.07%-1.51K
Lazard US Sm Cap Eq WW Dist EUR176.06K0.98%27.20K
Fidelity Small Cap Index177.76K0.98%783.00

Recent Insider Transactions


DateNameRoleActivityValue
Feb 20, 2026MOOS WALTER H-Sell$145.44K
Feb 05, 2025Schorno Dean L EVP & Chief Financial OfficerSell$38.02K
Feb 04, 2025Schorno Dean L EVP & Chief Financial OfficerSell$42.60K
Feb 04, 2025Santos David A EVP, Chief Commercial OfficerSell$44.46K
Feb 05, 2025Santos David A EVP, Chief Commercial OfficerSell$39.38K

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q2--
2025 Q1-8

RIGL Ownership FAQ


Who Owns Rigel Pharmaceuticals?

Rigel Pharmaceuticals shareholders are primarily institutional investors at 13.28%, followed by 2.43% insiders and 84.29% retail investors. The average institutional ownership in Rigel Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which Rigel Pharmaceuticals falls below.

Who owns the most shares of Rigel Pharmaceuticals?

Rigel Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (1.66M shares, 9.23%), Vanguard group (1.04M shares, 5.76%), and Armistice capital (724K shares, 4.05%). Together, they hold 19.03% of Rigel Pharmaceuticals’s total shares outstanding.

Does Blackrock own Rigel Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Rigel Pharmaceuticals.

Who is Rigel Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Cm management is Rigel Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 8.12% of its assets in 225K Rigel Pharmaceuticals shares, valued at 9.64M$.

Who is the top mutual fund holder of Rigel Pharmaceuticals shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Rigel Pharmaceuticals shares, with 4.07% of its total shares outstanding invested in 738.73K Rigel Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools